APR

FDA Grants Orphan Drug Designation to APR-OD031 for the Treatment of Phenylketonuria (PKU)

Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research s.a. ("APR"), the Swiss pharma company leveraging drug delivery technologies to develop innovative products for niche and rare diseases, today announced that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for the Company's drug candidate APR-OD031 for the treatment ...